Most big pharma companies have at least one amylin in development, the most advanced of which is Novo Nordisks CagriSema, a dual amylin/GLP-1 agonist currently under FDA review
(Israel), Fresenius Kabi AG (Germany), and STADA Arzneimittel AG (Germany)
The brainstem, spinal cord, hypothalamus, hippocampus, and retina of animals from various phyla exhibit the highest levels of glycine, an essential and extensively distributed inhibitory neurotransmitter (de Bartolomeis et al
Any substantial weight loss (on a GLP-1 or not) sheds some lean mass alongside fat
Traveling with GLP-1 medications requires advance planning to maintain proper storage conditions throughout the journey
J Neuroinflammation 11:177